Ariad Pharmaceuticals Inc fka ARIA

[BTH]

I just searched this board and wasn't able to find one instance of a post containing the term "$65"

When anyone uses the term "poison pill", it's safe to say they're speaking of "$65".

As far "palifosfamide + doxorubicin", having "longer PFS and improved patient stability", wasn't this what Ridaforolimus was originally for?

Perhaps Ariad management should have been smart enough to use Rida in combination with another drug for their Phase 3 study. Instead, they didn't have the money, nor the expertise, to figure this out early on with Defor (Rida), so, now, they are stuck with a single-agent mTOR in Phase 3 which is a lot less likely to work than with a combination.

So what you're saying is if the ZIOP study shows greater efficacy in the maintainence setting, than the SUCCEED trial, this will somehow help Ariad?